{"title":"Efficacy and safety of repeated synthetic mid-urethral sling for recurrent stress urinary incontinence: A systematic review and metanalysis","authors":"Alessandro Ferdinando Ruffolo , Tomaso Melocchi , Matteo Frigerio , Chrystele Rubod , Yohan Kerbage , Xavier Deffieux , Marine Lallemant , Michel Cosson","doi":"10.1016/j.ejogrb.2025.02.034","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>There is no clinical consensus concerning the best surgical procedure for recurrent stress urinary incontinence (rSUI) after primary mid-urethral sling (pMUS). The aim of this <em>meta</em>-analysis was to evaluate efficacy and safety of repeated MUS (rMUS) in women previously submitted to pMUS.</div></div><div><h3>Methods</h3><div>We performed systematic research and <em>meta</em>-analysis from PubMed/MEDLINE and EMBASE, according to PRISMA 2020 guidelines, until 11th of November 2024. Women with rSUI after pMUS, submitted to rMUS were included. Primary- versus repeated-MUS and retropubic (RP) versus transobturator (TO) approach were compared. rSUI cure and re-operation rates were evaluated. Seventeen articles were included.</div></div><div><h3>Key findings and limitations</h3><div>rMUS subjective and objective success rates were 68 % (95 %CI: 62 %-74 %; I<sup>2</sup>-test 70.3 %, <em>p</em> < 0.001) and 74 % (95 %CI: 66 %-82 %; I<sup>2</sup>-test 61.4 %, <em>p</em> = 0.003) respectively. No difference emerged between RP and TO approach subjectively [OR 0.92, 95 %CI 0.52–1.64; <em>p</em> = 0.78 (I<sup>2</sup>-test 34 %, <em>p</em> = 0.18)] and objectively [OR 0.80, 95 %CI 0.03–23.62; <em>p</em> = 0.90 (I<sup>2</sup>-test 79 %, <em>p</em> = 0.03)]. No difference was highlighted between pMUS and rMUS [OR 0.42, 95 %CI 0.16–1.09; <em>p</em> = 0.08 (I<sup>2</sup>-test 78 %, <em>p</em> = 0.03)] in subjective cure. No severe adverse events were reported. Reoperation rate for any indication was 5 % (95 %CI: 1 %-9%; I<sup>2</sup>-test 56.9 %, <em>p</em> = 0.04). Reoperation rate for rSUI was 1 % (95 %CI: 0 %-2%; I<sup>2</sup>-test 0.24 %, <em>p</em> = 0.37). Reoperation rate for other indications was 3 % (95 %CI: 1 %-4%; I<sup>2</sup>-test 10.9 %, <em>p</em> = 0.34).</div></div><div><h3>Conclusion</h3><div>rMUS is a highly effective and safe option for women with rSUI. Its excellent effectiveness, comparable to that of pMUS, and the lack of significant differences between RP and TO techniques underscore the flexibility and validity of this approach.</div></div>","PeriodicalId":11975,"journal":{"name":"European journal of obstetrics, gynecology, and reproductive biology","volume":"308 ","pages":"Pages 34-46"},"PeriodicalIF":2.1000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of obstetrics, gynecology, and reproductive biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0301211525001010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
There is no clinical consensus concerning the best surgical procedure for recurrent stress urinary incontinence (rSUI) after primary mid-urethral sling (pMUS). The aim of this meta-analysis was to evaluate efficacy and safety of repeated MUS (rMUS) in women previously submitted to pMUS.
Methods
We performed systematic research and meta-analysis from PubMed/MEDLINE and EMBASE, according to PRISMA 2020 guidelines, until 11th of November 2024. Women with rSUI after pMUS, submitted to rMUS were included. Primary- versus repeated-MUS and retropubic (RP) versus transobturator (TO) approach were compared. rSUI cure and re-operation rates were evaluated. Seventeen articles were included.
Key findings and limitations
rMUS subjective and objective success rates were 68 % (95 %CI: 62 %-74 %; I2-test 70.3 %, p < 0.001) and 74 % (95 %CI: 66 %-82 %; I2-test 61.4 %, p = 0.003) respectively. No difference emerged between RP and TO approach subjectively [OR 0.92, 95 %CI 0.52–1.64; p = 0.78 (I2-test 34 %, p = 0.18)] and objectively [OR 0.80, 95 %CI 0.03–23.62; p = 0.90 (I2-test 79 %, p = 0.03)]. No difference was highlighted between pMUS and rMUS [OR 0.42, 95 %CI 0.16–1.09; p = 0.08 (I2-test 78 %, p = 0.03)] in subjective cure. No severe adverse events were reported. Reoperation rate for any indication was 5 % (95 %CI: 1 %-9%; I2-test 56.9 %, p = 0.04). Reoperation rate for rSUI was 1 % (95 %CI: 0 %-2%; I2-test 0.24 %, p = 0.37). Reoperation rate for other indications was 3 % (95 %CI: 1 %-4%; I2-test 10.9 %, p = 0.34).
Conclusion
rMUS is a highly effective and safe option for women with rSUI. Its excellent effectiveness, comparable to that of pMUS, and the lack of significant differences between RP and TO techniques underscore the flexibility and validity of this approach.
期刊介绍:
The European Journal of Obstetrics & Gynecology and Reproductive Biology is the leading general clinical journal covering the continent. It publishes peer reviewed original research articles, as well as a wide range of news, book reviews, biographical, historical and educational articles and a lively correspondence section. Fields covered include obstetrics, prenatal diagnosis, maternal-fetal medicine, perinatology, general gynecology, gynecologic oncology, uro-gynecology, reproductive medicine, infertility, reproductive endocrinology, sexual medicine and reproductive ethics. The European Journal of Obstetrics & Gynecology and Reproductive Biology provides a forum for scientific and clinical professional communication in obstetrics and gynecology throughout Europe and the world.